rhPTH Therapy for Low Turnover Bone Fragility

Stopped early · Phase 1

Conditions studied: Osteopetrosis

In brief

The purpose of this study is to determine how treatment with a new medication, recombinant human parathyroid hormone (rhPTH) affects calcium balance and bone strength.

Key facts

Study ID

NCT00145886

Run by

University of Chicago

People needed

2

Starts

2003-02-01

Expected to finish

2011-09-01

Last updated by the study team

2016-01-12

Who can join

Age: 20 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• :patients with history of increased bone fragility by BMD criteria (T score > -1). In addition, the subjects will be enrolled only if they have clear evidence of low bone turnover as indicated by low normal levels of biochemical markers of bone turnover and finding of low bone turnover on bone biopsy. Each subject and his/her treating physician will have agreed that the rhPTH is the best treatment for the patient. Treatment with rhPTH will be considered only if the bone histomorphometry reveals a low turnover state and excludes other known forms of bone disease such as osteomalacia.

You may not qualify if…

• Subjects who are pregnant or younger than 20 will be excluded. Subjects cannot have osteoporosis

Where it is running

• University of Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.